SEC Form 4 · accession 0001193125-26-258436
MBX Biosciences, Inc. · MBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ora H. Pescovitz
Director
Period of report
Jun 4, 2026
Accepted (ET)
Jun 5, 2026 · 7:59 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001776111
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 24,329 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $30.91 | Jun 4, 2026 | A | 12,500 | A | — | Jun 4, 2036 | Common Stock | 12,500 | 12,500 | D |
Explanation of responses
- F1The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.